Eli Lilly and Company announced five-year outcomes from a pre-planned analysis of the Phase III monarchE study evaluating two years of adjuvant Verzenio (abemaciclib) in combination with endocrine… read more.
In patients with prostate cancer with high-risk biochemical recurrence, enzalutamide plus standard-treatment leuprolide is superior to leuprolide monotherapy for metastasis-free survival. And enzalutamide monotherapy is also superior to… read more.
Novartis will present new data from 29 Novartis and investigator-led abstracts at the European Society for Medical Oncology (ESMO) Congress 2023, highlighting latest developments from across its oncology… read more.
Takeda announced that, following discussions with the FDA, it will be working with the FDA towards a voluntary withdrawal of Exkivity (mobocertinib) in the U.S. for adult patients… read more.
BeiGene, Ltd. announced that the European Commission (EC) has approved Tevimbra (tislelizumab) as monotherapy for the treatment of adult patients with unresectable, locally advanced or metastatic esophageal squamous… read more.
Seagen Inc. and Astellas Pharma Inc. announced positive topline results from the Phase III EV-302 clinical trial (also known as KEYNOTE-A39) for Padcev (enfortumab vedotin-ejfv) in combination with… read more.
People who engage in sexual activity or vaginal dilation after chemoradiation treatment for cervical cancer are at lower risk for long-term side effects, according to a new study… read more.
Researchers at Dana-Farber Brigham Cancer Center have found that a shorter course of radiation therapy after mastectomy and breast reconstruction surgery provides the same protection against breast cancer recurrence and… read more.
Clinicians treating cancer-related pain must consider whether and how to prescribe opioids to patients who use nonmedical stimulants such as cocaine and methamphetamines; however, no guidelines exist related… read more.
One radiologist supported by AI detected more cases of breast cancer in screening mammography than two radiologists working together, reports the ScreenTrustCAD study from Karolinska Institutet in The Lancet… read more.
Seagen Inc. and Genmab A/S announced that the Phase III innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line… read more.
For roughly 80% of breast cancer survivors, treatment doesn’t end with surgery, radiation and chemotherapy. Instead, for the next five to 10 years, doctors recommend that they take… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
